retracted
Обзоры литературы
doi: 10.25005/2074-0581-2012-14-2-174-181
Гормонально-метаболическая концепция патогенеза заболеваний предстательной железы

И.А. Тюзиков, С.Ю. Калинченко*

ООО «Медицинский центр диагностики и профилактики», Ярославль
*кафедра эндокринологии ФПКМР РУДН, Москва, Россия

Метаболический синдром – комплексное понятие, включающее целый ряд, находящихся в патогенетической связи, метаболических факторов (абдоминальное ожирение, дислипидемия, эндотелиальная дисфункция, атеросклероз, артериальная гипертония, сахарный диабет 2 типа, системное хроническое воспаление, а у мужчин – ещё и низкий уровень тестостерона). Он тесно связан с патогенезом заболеваний предстательной железы, и их патофизиологические взаимоотношения рассматриваются в данном обзоре. Урологи и эндокринологи должны быть осведомлены о роли метаболического синдрома в происхождении заболеваний предстательной железы, поскольку новое понимание патогенеза урологических заболеваний и их патогенетическое лечение и профилактика в настоящее время возможны только на основе междисциплинарного подхода.

Ключевые слова: метаболический синдром, предстательная железа, сахарный диабет 2 типа, ожирение, гипогонадизм, доброкачественная гиперплазия простаты, хронический простатит.

Скачать файл:

Литература
  1. Demir O. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome / О. Demir, К. Akgul, Z. Akar // Aging Male.- 2009.- №12.- Р. 29–34
  2. Michel M.C. Association of hypertension with symptoms of benign prostatic hyperplasia / M.C. Michel, U. Heemann, H. Schumacher // J. Urol. - 2004. - №172. - Р.1390–1393
  3. Temml C. Are lower urinary tract symptoms influenced by metabolic syndrome? / C. Temml, R. Obermayr, M. Marszalek // Urology. -2009. -№73. - Р.544–548
  4. Gorbachinsky I. Metabolic Syndrome and Urological Deseases / I.Gorbachinsky H. Akpinar, D.G. Assimos // Rev. Urol. -2010.- №12(4). -Р. 157-180
  5. Gupta A. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans / A. Gupta, S. Gupta, M. Pavuk, C.G. Roehrborn // Urology. - 2006. - №68. - Р.1198–1205
  6. Haider A. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men / A. Haider, L.J. Gooren, P. Padungtod, F.Saad // Andrologia. - 2009. - №41. - Р. 7–13
  7. Karazindiyanoğlu S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic lateonset hypogonadism / S.Karazindiyanoğlu, S.Cayan // Aging Male. -2008. - №11(3). - Р. 146-149
  8. Назаров Т.Н. Диагностика и лечение возрастного андрогенного дефицита: дисс…д-ра мед. наук / Т.Н. Назаров. - СПб. - 2000. - 37 с.
  9. Шустер П.И. Возрастной андрогенный дефицит – один из ведущих этиологических факторов уролитиаза у мужчин /П.И. Шустер // Материалы IV Всероссийского Конгресса «Мужское здоровье». – М., 2008. - С. 37-38
  10. Alexandraki K. Inflammatory process in type 2 diabetes: the role of cytokines / K .Alexandraki, С. Piperi, С. Kalofoutis // Ann. NY Acad. Sci.- 2006. - №1084. - Р.89–117
  11. Cornu J.N. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines / J.N. Cornu, О. Cussenot, F.Haab, B. Lukacs // Eur. Urol. - 2010. - №58(3). - Р. 450-456
  12. Golden S.H. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review / S.H. Golden, K.A. Robinson, I. Saldanha // J. Clin. Endocrinol. Metab. -2009. -№94.- Р.1853–1878
  13. Kalinchenko S. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study / S. Kalinchenko , E.L. Vishnevsky, A.N. Koval // Aging Male. - 2008. - №11. - Р. 57–61
  14. Martin-Cordero L. Influence of exercise on the circulating levels and macrophage production of IL-1beta and IFNgamma affected by metabolic syndrome: an obese Zucker rat experimental animal model / L. Martin-Cordero, J.J.Garcia, E. Giraldo // Eur. J. Appl. Physiol. - 2009.- №107. - Р.535–543
  15. McVary K.Т. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology / K.Т. McVary// BJU Int. - 2006. - №97, Suppl. 2. - Р. 23–28
  16. Ozden C. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia /С. Ozden, O.L. Ozdal, G.Urgancioglu // Eur. Urol. - 2007. - № 51. - Р.199– 203
  17. Robert G. Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis / G. Robert, A. Descazeaud, N.Nicolaïew // Prostate. - 2009. - №69. - Р.1774–1780
  18. Srikanthan P. Relative Muscle Mass Is Inversely Associated withInsulin Resistance and Prediabetes. Findings from The Third National Health and Nutrition Examination Survey / P. Srikanthan, A.S. Karlamangla // J. Clin. Endocrin. Metab. - First published ahead of print July 21, 2011 as doi:10.1210/jc.2011-0435
  19. Alberti G. Introduction to the metabolic syndrome / G. Alberti // Eur. Heart J. - 2005. - №7(suppl D). - Р.3–5
  20. Ho C.K. Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen / C.K. Ho, J. Nanda, K.E. Chapman, F.K. Habib // J. Endocrinol.- 2008. - №197. - Р. 483–491
  21. Geiss L.S. Changes in incidence of diabetes in U.S. adults, 1997–2003 / L.S. Geiss, L. Pan, B. Cadwell // Am. J. Prev. Med.- 2006. - №30. - Р.371–377
  22. Sturm R. Increases in clinically severe obesity in the United States, 1986–2000 / R. Sturm // Arch. Intern. Med. - 2003. - №163. - Р.2146–2148
  23. Flegal K.M. Prevalence and trends in obesity among US adults, 1999–2000 / K.M. Flegal, M.D. Carrol, C.L. Ogden, C.L. Johnson // JAMA. - 2002. - №288. -Р. 1723–1727
  24. Huang P.L. A comprehensive definition for metabolic syndrome / P.L. Huang // Dis. Model Mech. -2009. - №2. -Р. 231–237
  25. Low S. Review on epidemic of obesity / S. Low, M.C. Chin, M. Deurenberg-Yap // Ann. Acad. Med. Singapore. - 2009. - №38. - Р.57–59
  26. Termizy H.M. Metabolic syndrome and its characteristics among obese patients attending an obesity clinic / H.M. Termizy, M.Mafauzy // Singapore Med. J.- 2009. - №50. - Р. 390–394
  27. Grundy S.M. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement / S.M. Grundy, J.I. Cleeman, S.R.Daniels // Circulation.- 2005.- №112. - Р. 2735–2752
  28. Leibson C.L. Relative contributions of incidence and survival to increasing prevalence of adult-onset diabetes mellitus: a population-based study /C.L. Leibson, P.C. O’Brien, Е.Atkinson // Am. J. Epidemiol.- 1997. -№146. - Р.12–22
  29. Malik S. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults / S.Malik, N.D. Wong, S.S. Franklin // Circulation.- 2004. -№110. - Р.1245–1250
  30. Mokdad A.H. Diabetes trends in the U.S.: 1990–1998 / A.H. Mokdad, E.S. Ford, B.A. Bowman // Diabetes Care. - 2000. - №23.- Р.1278–1283
  31. Lee M.J. Integration of hormonal and nutrient signals that regulate leptin synthesis and secretion / M.J. Lee, S.K. Fried // Am. J. Physiol. Endocrinol. Metab. - 2009. - №296.- Р.1230–1238
  32. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis / L. Landsberg // Q. J. Med. -1986. - №61.- Р.1081–1090
  33. McVary K. The association of lower urinary tract symptoms (LUTS) with sexual function in men participating in a clinical trial of medical therapy for benign prostatic hyperplasia / К.McVary, О.М. Bautista, J.Kusek // J. Urol. -2003. - №169 (Suppl). - Р. 322
  34. Rhoden E.L. Evaluation of the association between lower urinary tract symptoms and erectile dysfunction, considering its multiple risk factors / E.L.Rhoden, C.E. Riedner, А. Fornari, S.C. Fuchs, E.P. Ribeiro // J. Sex Med. - 2008.- №5(11).- Р. 2662-2668
  35. Rohrmann S. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III) / S. Rohrmann, А.М. De Marzo, Е. Smith // Prostate.- 2005. - №62. - Р.27–33
  36. Чупрына П.С. Доброкачественная гиперплазия простаты, осложнённая ОЗМ, и уровень тестостерона крови / П.С. Чупрына, В.И. Деревянченко, С.В.Щелков// Материалы IV Всероссийского конгресса «Мужское здоровье». – М., 2008. - С. 66-67
  37. Корнеев И.А. Уровень тестостерона и расстройства мочеиспускания у больных с доброкачественной гиперплазией предстательной железы / И.А. Корнеев, С.Ю. Глазнева // Материалы IV Всероссийского конгресса «Мужское здоровье».- М., 2010.- С.49-50
  38. Yassin A.A. Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone / A.A. Yassin, A.I. El-Sakka, F. Saad, L.J. Gooren // Andrologia. - 2008. - №40. - Р.259–264
  39. Kupelian V. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey / V. Kupelian, K.T. McVary, S.A.Kaplan // J. Urol.- 2009. - №182. - Р.616–624
  40. EAU BHP Guidelines / M. Oelke [at al.]. EAU, 2010 April. - 38 p.
  41. Rohrmanns S. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III) /S. Rohrmanns, W.G. Nelson, N. Rifai // Urology.- 2007. -№ 69. - Р.708–713
  42. Hammarsten J. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia / J. Hammarsten, B.Högstedt, N.Holthuis, D.Mellström // Prostate Cancer Prostatic Dis.- 1998.- №1. - Р. 157–162
  43. Tomita K. Lower urinary tract symptoms in relation to lifestyle and medical conditions in Japanese workers / К.Tomita, Т. Mizoue, Т.Matsumoto // Int. J. Urol. - 2009. - №16. - Р.493–498
  44. McVary K.T. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia / K.T. McVary, А. Rademaker, G.L. Lloyd, P. Gann // J. Urol. - 2005. - №174(4), Pt 1. - Р. 1327–1433
  45. Niskanen L. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome / L.Niskanen, D.E. Laaksonen, K. Punnonen // Diabetes Obes. Metab. -2004. - №6. - Р.208–215
  46. Azadzoi K.M. Chronic ischemia increases prostatic smooth muscle contraction in the rabbit / K.M. Azadzoi, R.K. Babayan, R. Kozlowski, M.B. Siroky // J. Urol. - 2003. - №170, Pt. 1. - Р. 659–663
  47. Azadzoi K.M. Atherosclerosis-induced chronic ischemia causes bladder fibrosis and non-compliance in the rabbit / K.M. Azadzoi, T. Tarcan, M.B. Siroky, R.J. Krane // J. Urol.- 1999.- №161.- Р.1626-1635
  48. Kozlowski R. Chronic ischemia alters prostate structure and reactivity in rabbits / R. Kozlowski, R.T. Kershen, M.B. Siroky // J. Urol. - 2001. -№165. - Р.1019–1026
  49. Ansari M.A. Serum sex steroids, gonadotrophins and sex hormonebinding globulin in prostatic hyperplasia / М.А. Ansari, D.Begum, F. Islam // Ann. Saudi Med.- 2008.- №28. - Р.174–178
  50. Fibbi B. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia / В. Fibbi, G. Penna, А. Morelli // Int. J. Androl. - 2010.- №33.- Р. 475–488
  51. Rees R.W. Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells / R.W. Rees, N.A. Foxwell, D.J. Ralph // J. Urol. - 2003. - №170(6), Pt 1. - Р. 2517–2522
  52. Penna G. Rho kinase: a target for treating urinary bladder dysfunction? / G. Penna, B. Fibbi, S.Amuchastegui // Trends Pharmacol Sci. - 2006. - №27. - Р. 492–497
  53. Sauzeau V. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle / V.Sauzeau, H. Le Jeune, C.Cario-Toumaniantz // J. Biol. Chem. - 2000. - №275. - Р. 21722–21729
  54. Takahashi R. RhoA/Rho kinase-mediated Ca2+ sensitization in the contraction of human prostate / R. Takahashi, J.Nishimura, N.Seki // Neurourol Urodyn.- 2007.- №26.- Р.547–551
  55. Penna G. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways / G. Penna, B. Fibbi, S. Amuchastegui // Prostate.- 2009.- №69. -Р.480–493
  56. Oreste M. Betweensubject variations of transition zone epithelial volume and serum PSA levels in men with benign prostatic hyperplasia / М. Oreste, P.G. Giuseppe, Р. Gianna // World J. Urol. - 2010. - №28.- Р.379–383
  57. Smith P. Upregulation of estrogen and androgen receptors modulate expression of FGF-2 and FGF-7 in human, cultured, prostatic stromal cells exposed to high concentrations of estradiol / P.Smith, N.P. Rhodes, Y. Ke, C.S. Foster // Prostate Cancer Prostatic Dis. - 2002. - №5. - Р.105–110
  58. Schatzl G. Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology / G.Schatzl, C. Brössner, S.Schmid // Urology. - 2000. - №55. - Р.397–402
  59. Park I.I. 17Beta-estradiol at low concentrations acts through distinct pathways in normal versus BPHderived prostate stromal cells / I.I. Park, Q. Zhang, V. Liu // Endocrinology. - 2009.- №150. - Р.4594–4605
  60. Collin S.M. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screendetected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study / S.M.Collin, С. Metcalfe, J. Donovan // BJU Int.- 2008. - №102. - Р. 1400–1406
  61. Winter M.L. Possible mechanism of induction of benign prostatic hyperplasia by estradiol and dihydrotestosterone in dogs / M.L. Winter, J.G. Liehr // Toxicol. Appl. Pharmacol. - 1996. - №136. - Р.211–219

Адрес для корреспонденции:

И.А. Тюзиков
профессор Российской академии естествознания

Россия, г. Ярославль, пр. Ленина, д. 33

E-mail: phoenix-67@list.ru

◄ Возврат к списку